As we make progress with our own developments in exosome technology, Kimera Labs continues to collect scientific evidence about the nature of exosomes and their unique biologic properties. Kimera Labs will continue to support clinical studies on MSC exosomes and will complete investigational trials for exosome-based pharmaceutical products.



Indication-specific, engineered exosomes and optimized delivery systems for MSC exosomes are likely to play a significant role in the future of healthcare, and Kimera Labs is at the forefront of exosome technology development for regenerative medicine applications, all in support of health care providers and ultimately, their patients.